Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Published Online: 2016-06-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Alberto Bardelli•Alessio Amatu•Andrea Bertotti•Andrea Cassingena•Andrea Sartore-Bianchi•Angelo Vanzulli•Calogero Lauricella•Cosimo Martino•Daniele Regge•Emanuele Valtorta•Erika Martinelli•Fortunato Ciardiello•Francesca Bergamo•Francesco Leone•Giovanna Marrapese•Giulia Siravegna•Ilaria Depetris•Katia Bencardino•Laura Palmeri•Livio Trusolino•Paolo M Comoglio•Patrizia Racca•Salvatore Siena•Sara Lonardi•Silvia Ghezzi•Silvia Marsoni•Silvio Veronese•Teresa Troiani•Valter Torri•Vittorina Zagonel
